Market Place
Sourcing Support
All News #Library
Biotech
Tortugas Comes Out Of Shell With $106M, 4 Ph. 2-Stage Neuro Meds
21 Apr 2026 //
FIERCE BIOTECH
GSK Initiates 5 Phase 3 Trials For Hansoh`s Gynecological Cancer
13 Apr 2026 //
ENDPOINTS
Regeneron-Licensed Olatorepatide Shows Ph3 Obesity Data China
09 Mar 2026 //
GLOBENEWSWIRE
GSK Says `s Tuned` For More ADC Data As Hansoh Posts 49% ORR
19 Oct 2025 //
FIERCE BIOTECH
Regeneron Expands Clinical-Stage Obesity Portfolio
02 Jun 2025 //
PRESS RELEASE
Hansoh Pharma Expands Merigolix Indications with ART Development
20 Mar 2025 //
PR NEWSWIRE
Silence slows zerlasiran, as Hansoh leaves $1.3B biobucks collab
28 Feb 2025 //
FIERCE BIOTECH
Merck signs up to $2 bln obesity drug deal with biotech Hansoh
19 Dec 2024 //
REUTERS
Jiangsu Hansoh ADC HS-20093 Holds In SCLC 2nd-Line Treatment
22 Nov 2024 //
EXPRESSPHARMA
Hansoh signs $690M ADC pact with fellow Chinese biotech Biotheus
16 Mar 2024 //
FIERCE PHARMA
Biotheus Expanded Their Partnership with Hansoh Pharma
15 Mar 2024 //
PR NEWSWIRE
GSK enters exclusive license agreement with Hansoh for HS-20093
21 Dec 2023 //
PRESS RELEASE
GSK enters exclusive license agreement with Hansoh for HS-20089
21 Oct 2023 //
PRESS RELEASE
Hansoh Pharma’s Saint Luolai granted approval for marketing
05 Jul 2023 //
PRESS RELEASE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.